Month: January 2026

Why Most Testosterone Gels Don’t Work (& What Makes Transcrotal Cream Different)

Posted on by AmyADMIN

Topical testosterone (like testosterone gel or cream) is often marketed as the “easy” option for testosterone replacement therapy. No injections, no needles, just a daily application and you’re done. Sounds great, right? Unfortunately, many men walk away feeling frustrated. 

They experience inconsistent results, symptoms that don’t improve, and levels that barely move. Eventually, they conclude that topical testosterone doesn’t work. In most cases, that conclusion misses the real issue.

The problem usually isn’t topical testosterone itself. It’s which topical product was used, how it was formulated, and how it was prescribed. Commercial testosterone gels and compounded testosterone creams are not the same therapy, even though they’re often lumped together.

In an episode of the Women Want Strong Men podcast, hormone expert Dave Lee breaks down why formulation, dosing, absorption, and stability matter so much with topical testosterone. You can save the full episode to dive deeper after reading.

Topical Testosterone Isn’t All the Same

One of the biggest sources of confusion around topical testosterone is the language. When patients say “testosterone cream,” they’re often referring to very different products.

Broadly, topical testosterone falls into two categories:

  • Commercially available testosterone gels
  • Compounded testosterone creams

They behave differently in the body and produce very different results.

What Is Testosterone Gel? 

Commercial testosterone gels are FDA-approved topical products commonly prescribed by primary care providers and urologists. These are the options most often covered by insurance.

They are designed to be broadly tolerated and easy to prescribe, which usually means:

  • Low testosterone concentration
  • Conservative dosing
  • Application to large surface areas (arms, shoulders, torso)
  • Standardized formulations for mass use

These products are often what men are referring to when they say topical testosterone “didn’t work.” Despite being marketed as convenient, many men find testosterone gels frustrating in real life. 

Common complaints include:

  • Feeling greasy or sticky after application
  • Worrying about sweating the medication off
  • Transfer risk to partners or children
  • Daily application with little noticeable benefit

Because the doses are low and absorption is inconsistent, many men never experience meaningful symptom improvement. Over time, compliance drops because the hassle outweighs the perceived benefit. This is not a failure of testosterone as a therapy. It’s a limitation of how commercial gels are designed and prescribed.

What Is Compounded Testosterone Cream?

Compounded testosterone creams are a completely different category of therapy. These products are made by compounding pharmacies and allow for:

  • Higher testosterone concentrations
  • Smaller application areas
  • Customized dosing based on labs and symptoms
  • Cream bases designed for improved absorption

When compounded properly, testosterone creams can deliver far more consistent and effective results than commercial gels. That said, quality matters. The compounding pharmacy plays a major role in outcomes. 

Consistency between batches, the stability of the formulation, and the choice of cream base all affect absorption and reliability. A poorly compounded product can lead to inconsistent dosing even if everything else is done right.

Just as important is the provider managing the therapy. Absorption varies from person to person, and dosing often needs to be adjusted over time based on follow-up labs and symptom response. Without proper monitoring, even high-quality compounded creams can fall short.

Why Commercial Testosterone Gels Often Fail

Many men come to us after using commercial gels and wonder whether topical testosterone therapy is even worth considering. We’ll tell you what we tell them: if you’re applying it daily and exactly as instructed, the problem might be the protocol itself. 

Commercial testosterone gels often fail because:

  • They are dosed conservatively by design.
  • Absorption is inconsistent across large skin areas.
  • Formulations prioritize safety and scalability over optimization.
  • Daily application becomes burdensome when results are minimal.

Even when men do everything right, their testosterone levels may barely move. Symptoms like fatigue, low libido, and poor recovery remain unchanged. Over time, frustration builds and therapy is abandoned. These limitations are specific to low-potency commercial gels, not topical testosterone as a whole.

What Makes Transcrotal Testosterone Cream Different?

Among compounded testosterone creams, transcrotal application behaves differently because the skin behaves differently. The skin of the scrotum is significantly thinner and more permeable than other areas of the body. This allows testosterone to absorb far more efficiently compared to standard application sites.

Key differences of transcrotal testosterone cream include:

  • Much higher absorption rates (because this area is thin and vascular)
  • Smaller doses required to achieve meaningful levels
  • Higher-concentration compounded formulations (often 10-20%)
  • More predictable and stable testosterone delivery

Because absorption is so efficient, transcrotal cream can deliver steadier testosterone levels with less variability. Many men who failed commercial gels do very well with this approach when it’s prescribed and monitored correctly.

Who Topical Testosterone May Be Best For

Topical testosterone isn’t inherently better or worse than injections or pellets. It’s simply another tool. Like any tool, it works best when matched to the right patient and prescribed with intention.

Properly compounded topical testosterone can deliver:

  • Ultra-stable testosterone levels with fewer peaks and troughs
  • Needle-free therapy, which many patients prefer long term
  • Minimal ingredients, using bio-identical testosterone in a hypoallergenic cream base
  • A more favorable lipid response, with some patients seeing improvements in HDL cholesterol compared to injectable therapy

Because topical testosterone is absorbed gradually through the skin, it often produces steadier hormone levels throughout the day. This stability can be especially helpful for men who are sensitive to hormonal swings or who experience side effects from fluctuating testosterone levels.

That said, topical therapy still requires thoughtful dosing, high-quality compounding, and regular follow-up. When those elements are in place, topical testosterone can be a powerful and well-tolerated option for long-term hormone optimization.

Start Your Testosterone Journey the Right Way

Most testosterone gels fail not because topical therapy doesn’t work, but because they’re low-potency, inconsistently absorbed, and poorly matched to patient physiology. Many men never truly experience optimized testosterone levels while using them.

Properly compounded testosterone creams, including transcrotal formulations, are a different therapeutic tool altogether. When formulation quality, dosing, and follow-up are handled correctly, topical testosterone can be just as effective as injections for the right patient.

At Victory Men’s Health, we start with comprehensive labs to determine which delivery method makes the most sense for you. If topical therapy is appropriate, we focus on pharmacy quality, absorption, dosing, and ongoing adjustments so results improve over time.

Ready to get clarity on whether topical testosterone is right for you? Schedule a consultation with our team to review your labs and build your personalized treatment plan.

What Big Pharma Companies Don’t Want You To Know About TRT

Posted on by AmyADMIN

Big pharma companies have played a major role in shaping how testosterone replacement therapy is talked about and regulated. Over time, that influence has created a simplified story around TRT: if your testosterone seems low, replacement is the obvious answer. 

At the same time, TRT policy and clinical guidelines often paint testosterone as something dangerous or controversial, leaving many men stuck between hype and hesitation. One side makes TRT sound like a cure-all, the other treats it like a last resort. Neither approach reflects how testosterone really works in the body.

The truth is far more complex. Testosterone replacement can be life-changing for the right man when prescribed the right way, for the right reasons. It can also fall flat or create problems when it’s treated as a shortcut instead of a medical tool. 

In an episode of the Women Want Strong Men podcast, we sat down with hormone expert Dave Lee to discuss how testosterone therapy became so oversimplified, where most protocols go wrong, and what optimized care looks like. Save the full episode below to dive deeper.

Do Big Pharma Companies Oversimplify TRT?

Big pharma companies don’t need to invent testosterone deficiency to benefit from TRT. All they need to do is make the solution feel straightforward: a low number on a lab report, a prescription, and big promises of better energy and performance.

That simplicity makes testosterone easier to market and scale, and it also strips away important context. Testosterone is not a vitamin deficiency. It’s a hormone that interacts with nearly every system in the body, including metabolism, heart health, sleep, mood, and fertility.

When TRT is framed as a universal fix, expectations rise fast. Men assume that starting therapy will automatically resolve fatigue, brain fog, low motivation, or stubborn weight gain. When those changes don’t happen, testosterone gets blamed, even though the issue is more complex.

Why Big Pharma and TRT Policy Focus on Numbers, Not Outcomes

TRT policy is built around population-level safety and averages of normal, not individual optimization. From a regulatory standpoint, that makes sense. Numbers are easy to define and standardize across large populations. Total testosterone cutoffs are a perfect example. 

They create a clear line between “low” and “normal,” even though men don’t experience hormones in binary terms. Two men with the same total testosterone level can feel different depending on their SHBG, free testosterone, androgen receptor density, metabolic health, sleep, stress, and lifestyle.

This number-first approach helps explain why testosterone stigma still exists in medicine today. When men are treated based on thresholds instead of outcomes, results are inconsistent. TRT ends up labeled as unpredictable or risky, when the real issue is that male physiology is being reduced to a single data point.

Why the “Low Testosterone Fix” Often Falls Short in Real Life

Many men start TRT expecting an instant and dramatic transformation. Some feel an initial boost. Others feel very little. Some feel worse over time. That wide range of outcomes is one of the biggest reasons men grow skeptical of big pharma and TRT messaging.

Testosterone is often prescribed in isolation. If fatigue, low motivation, or weight gain are being driven by something else, replacing testosterone alone won’t fix the underlying issue. It may improve a lab value while leaving your symptoms unchanged.

Common reasons TRT doesn’t deliver the results men expect include:

  • Sleep apnea or poor sleep quality
  • Insulin resistance or metabolic dysfunction
  • Thyroid or adrenal issues that were never evaluated
  • Chronic stress and poor recovery
  • Inflammation or nutrient deficiencies

Another issue is timing: hormonal adaptation takes time. Testosterone affects your red blood cells, neurotransmitters, muscle tissue, fat metabolism, and cardiovascular function. Expecting full optimization in a few weeks sets men up for disappointment. 

TRT is not a switch you flip. It’s a long-term physiological adjustment.

Is TRT Really the Problem… Or Is It the Protocol?

Most of the side effects blamed on TRT can be traced back to how it’s prescribed and managed. Infrequent dosing, large hormonal swings, minimal follow-up, and cookie-cutter protocols create instability. Instability creates symptoms.

When testosterone levels spike and crash, men may experience sleep disruption, mood changes, excess sweating, acne, or cardiovascular strain. Those effects often get attributed to testosterone itself, reinforcing fear-based narratives and tighter TRT policy.

But stable dosing, proper titration, and consistent monitoring completely change the picture. Testosterone works best when levels are steady and the rest of the system is prepared to handle the increase. In most cases, it’s not testosterone causing the problem. It’s volatility.

Why Do Some Men Feel Worse on TRT?

One of the biggest misconceptions created by oversimplified TRT messaging is that all men will respond the same way. In reality, response to testosterone varies widely from person to person. Two men can be prescribed the same dose and have completely different experiences. 

Here are some key factors that influence how a man responds to TRT:

  • SHBG levels and how much testosterone is actually bioavailable
  • Liver and thyroid function, which affect hormone metabolism
  • Insulin sensitivity and overall metabolic health
  • Age and baseline hormone exposure
  • Training volume, stress load, and recovery capacity

This variability is why replacement-only approaches often fall short. Optimization requires adjusting based on labs, symptoms, and real-world response over time. Some men feel best within the reference range, while others feel best slightly above it. There is no universal target, only an individual response that needs to be respected.

How to Know If TRT Is Right for You

TRT can be an effective tool, but it’s not always the first or best move. Instead of asking if you qualify for therapy, ask why your testosterone is low in the first place. Many factors can suppress testosterone temporarily or chronically. Addressing those factors first can sometimes improve your levels enough to resolve symptoms without lifelong hormone therapy.

TRT may not be the right first step if low testosterone is being driven by:

  • Poor sleep or untreated sleep apnea
  • Excess body fat or insulin resistance
  • High stress and low recovery
  • Alcohol overuse
  • Inadequate nutrition or micronutrient deficiencies

TRT becomes more appropriate when testosterone deficiency is persistent, symptomatic, and unlikely to resolve with lifestyle changes alone. That decision should be guided by comprehensive labs, symptom context, and a clear long-term plan. 

Testosterone Optimization Starts Here

Despite what big pharma companies might have you believe, testosterone isn’t something every man needs. But it also isn’t something to fear when it’s the right fit. When TRT is reduced to a lab number or framed as a universal fix, men are left confused or overly cautious. Real progress starts when testosterone is understood as part of a larger system, not a standalone solution.

At Victory Men’s Health, we start with comprehensive labs to help determine whether testosterone is the right tool for you. If TRT makes sense, we focus on stable dosing, titration, and long-term monitoring so your results improve over time. If you’re considering TRT or already on it and not feeling the way you hoped, we can help you get clarity. 

Ready to take the first step? Book a consultation today to take control of your hormone health with a team that prioritizes outcomes over shortcuts.

Research Use Only Peptides: Why the FDA Is Ending the RUO Era

Posted on by AmyADMIN

If you’ve spent any time around peptides over the last few years, you’ve probably seen the phrase “Research Use Only” everywhere from vials to websites to influencer posts. Often paired with the fine print: not for human use.

That label created a loophole. And for a while, it worked…but that era is coming to a close. The FDA is shifting its focus away from surface-level marketing violations to instead focus on how injectable peptides are actually being made, handled, and sourced. 

For patients, this shift matters more than any warning letter ever could. Today, we’re breaking down everything you need to know about research use only peptides, why they exploded in popularity, and why we believe medically supervised peptide therapy is the only path forward.

What Are Research Use Only (RUO) Peptides?

“Research Use Only” is not a quality standard and never was. RUO peptides are chemical compounds labeled and sold for laboratory research, not for use in humans. The label exists to define intended use, not to guarantee purity, sterility, dosing accuracy, or safety.

Over time, that distinction blurred. Many RUO peptides were marketed in ways that clearly appealed to human consumers: weight loss, fat loss, muscle gain, cognitive enhancement. 

Influencers shared their go-to protocols and promo codes, and that disclaimer stayed—quietly covering everyone involved from a legal perspective. From a patient POV, the label created a false sense of reassurance. If it’s being sold everywhere, it must be safe enough…right?

That assumption is what regulators are now dismantling. 

Short answer: no. RUO (Research Use Only) peptides are not approved for human use. The label exists so companies can sell pharmaceutical compounds without prescriptions, pharmacies, or medical oversight.

These products are often sold direct-to-consumer, shipped to your home, and used without physician guidance or proper quality controls. This has never been considered a safe model for patient care.

Many people hear about RUO peptides from influencers, bodybuilders, or gym acquaintances who present them as a cheaper alternative to prescribed peptides. What’s missing from that pitch is the lack of regulation, accountability, and safety standards.

“Research use only” doesn’t make a compound safe for injection. It simply removes oversight.

That’s especially true with injectables. Regulators don’t just care what a vial says. They care how it’s promoted and manufactured, and how it moves through the supply chain. When those pieces don’t align, FDA enforcement follows, which is exactly what’s happening now.

Why Is the FDA Cracking Down on RUO Peptides Now?

For years, FDA peptide enforcement focused on websites and marketing claims. Were sellers implying human use? Were they advertising outcomes they couldn’t substantiate? That was the first phase, but the phase we’re at now is more serious.

Regulators are now looking upstream, at manufacturing and supply chains. And when they look there, many RUO peptide operations simply don’t hold up. Injectable products dramatically raise the bar. Sterility, traceability, documentation, and quality controls are foundational. 

When those elements can’t be clearly demonstrated, regulators see medications being sold without prescriptions or medical oversight, which creates a major patient safety issue.

What Changed in the Supply Chain for RUO Peptides?

Many RUO peptide sellers don’t manufacture anything themselves. They rely on third-party labs, contract manufacturers, or overseas suppliers. In some cases, no single party has full visibility into where raw materials come from, how sterility is achieved, or how batches are tested. 

From a patient safety standpoint, that means there’s no reliable way to confirm:

  • Sterility
  • Accurate dosing
  • Purity
  • Contamination risk
  • Traceability if something goes wrong

For regulators, that’s a hard stop. And for patients, it means the phrase “you don’t know what’s in that vial” isn’t rhetorical.

What Are the Risks of Research Use Only Peptides?

Injectables bypass the body’s natural filtering systems. When something goes directly into your bloodstream, small inconsistencies matter more.

With RUO peptides, the most common risks include:

  • Mislabeling – The dose on the vial doesn’t match what’s inside
  • Potency variability – Under- or overdosing between batches
  • Contamination – Bacterial, endotoxin, or particulate contamination
  • No accountability – No recall system, no oversight, no recourse

These risks can (and often do) lead to serious issues like abscesses and sepsis. 

Many people used RUO peptides without obvious issues, but that doesn’t mean the system was sound, just that they were fortunate. Health-conscious people don’t gamble with mystery vials, especially when safer alternatives exist.

GLP-1 medications changed everything. Demand for weight loss exploded, and legitimate supply couldn’t keep up fast enough. RUO versions of semaglutide, tirzepatide, and experimental compounds quickly hit the market to fill the gap.

Some of these compounds, like retatrutide, are still in clinical trials. Early data is promising, but that doesn’t make them appropriate for unsupervised use. When massive demand collides with injectable medications and unregulated supply chains, scrutiny is inevitable. Regulators didn’t suddenly notice RUO peptides; the scale simply reached a tipping point.

Why Do People Use Peptide Therapy?

Most of our patients aren’t looking for shortcuts. They come to us because something feels off and the usual advice hasn’t gotten them where they want to be. They’ve tried cleaning up their diet, exercising more, or sleeping better, but they’re still struggling to see meaningful change.

Common reasons include:

  • Stubborn weight loss resistance
  • Fatigue and metabolic slowdown
  • Poor recovery or muscle loss
  • Inflammation and joint pain
  • Cognitive fog or performance decline
  • Aging-related changes that don’t respond to lifestyle alone

Peptides appeal to many people because they interact directly with biological pathways. When used appropriately, they can be powerful tools. The real issue is the absence of guardrails.

Who Is a Good Candidate for Peptide Therapy?

Peptide therapy works best for patients who want guidance, not guesswork. The people who see the best outcomes aren’t chasing trends or protocols they found online. They’re looking for a thoughtful, medically supervised approach that fits into a broader plan for their health.

Good candidates are often people who:

  • Want individualized dosing based on labs and clinical context
  • Value sterility, sourcing transparency, and consistency
  • Are already using or considering GLP-1 medications and want oversight
  • Prefer progress with monitoring rather than trial and error

Peptide therapy is most effective when it complements a strong foundation of nutrition and exercise. In that context, it can support body composition goals, healing and recovery, immune function, and healthy aging.

Peptides should always be prescribed, sourced through licensed pharmacies, and supported by ongoing clinical care. 

What Does Safe Peptide Therapy Look Like?

Safe Peptide Therapy Victory Men's Health

Safe peptide therapy starts with accountability. From who’s prescribing it to where it’s sourced and how it’s monitored, every step matters. That structure is what turns peptides from a gamble into a tool you can actually trust.

Injectable peptides should follow the same basic framework as any other medication:

  • Licensed clinician oversight
  • Prescription-based access
  • Licensed, regulated pharmacies
  • Ongoing monitoring and follow-up

That structure exists for a reason. If something changes, there’s documentation. If something goes wrong, there’s a path forward. This isn’t about bureaucracy. It’s about respecting the fact that these compounds alter our physiology.

Start Peptide Therapy the Right Way

Injectable compounds come with real responsibility, and the conversation around research use only peptides has finally shifted. Peptides themselves aren’t the issue. In fact, most peptides have very few side effects if done correctly. The lack of sourcing transparency, sterility standards, and oversight is the problem.

At Victory Men’s Health, we take an individualized approach to peptide therapy. We look at your labs, medical history, and goals, then build a plan that makes sense for your body. Whether peptides are part of your weight loss journey or performance plan, our focus is always on your safety and long-term progress.

If you’re currently using peptides or thinking about it, we’ll help you sort through the confusion. Book a consultation with our team today to talk through what’s safe and worth your time.

FDA Testosterone Panel: Are We Finally Done With Fear-Based TRT Policy?

Posted on by AmyADMIN

In December 2025, the FDA convened an expert panel to reexamine how testosterone replacement therapy (TRT) is labeled, regulated, and discussed in men’s healthcare.

For decades, testosterone has been burdened by warnings and restrictions that were never fully supported by data. Those policies didn’t just shape regulation. They shaped how doctors practice, how patients are counseled, and whether men get timely care at all.

TRT has lived in a gray area for years, and that hasn’t been harmless. 

We see it all the time: Fear-based policy delays diagnosis, creates confusion, and keeps men from getting care that could meaningfully improve their quality of life. Testosterone is widely prescribed and clearly beneficial for many men, yet it’s still treated with unnecessary suspicion.

We’re breaking down what actually came out of the FDA testosterone panel held in December 2025 and what it means if you’re considering testosterone therapy or already using it. And if you want to hear the full discussion firsthand, you can watch the complete session after reading.

What Was the FDA Testosterone Panel?

The FDA testosterone panel brought together experts in urology, sexual medicine, endocrinology, and men’s health to review how testosterone replacement therapy is currently labeled and regulated. 

It wasn’t about whether testosterone “works,” since that question has been answered. It was about whether decades-old warnings still reflect modern data or whether they’ve been standing in the way of appropriate care.

Panelists were asked to revisit long-standing concerns around prostate cancer, cardiovascular risk, and who should even be allowed to receive TRT. The conclusion was clear: Much of the existing TRT policy does not align with modern data or clinical practice.

That may sound new at the regulatory level, but it reflects what we have been seeing for years. Science has moved a lot faster than policy, and this panel was long overdue.

Why Is There a Testosterone Stigma?

Testosterone didn’t earn its stigma through evidence. It inherited it.

It’s been culturally linked to gyms, “meatheads,” and steroid abuse—then further distorted by the false idea that low T automatically means ED. It doesn’t. They can overlap, but they aren’t mutually exclusive.

That perception created real consequences: men stopped talking about symptoms, labs were downplayed, and many were discouraged from seeking care. Too often, primary care treats low testosterone as “not a real issue.” Over time, the narrative hardened into training and labeling that still influences care today—despite the science.

The FDA testosterone panel called out this disconnect between outdated beliefs and the reality that testosterone is a vital health marker that should be evaluated, not dismissed.

Does Testosterone Increase Prostate Cancer Risk?

Prostate cancer has been one of the most persistent fears tied to TRT, so it was a central topic during the FDA testosterone panel.

According to panel expert Dr. Abraham Morgentaler, Harvard urologist and pioneer researcher on testosterone and prostate cancer:

  • Testosterone is not a carcinogen.
  • Modern data does not show increased prostate cancer risk with properly monitored TRT.
  • Long-standing contraindications are based on outdated assumptions.

Despite this, FDA labeling still includes warnings that suggest TRT is unsafe for men with prostate cancer or even suspected prostate cancer. Panelists argued that these warnings are not supported by contemporary evidence and unnecessarily discourage appropriate care.

We’ve seen many patients who were scared out of treating their low testosterone symptoms after discussing it with a primary care doctor because the old narrative still gets repeated: TRT equals prostate cancer risk.

Evidence-based medicine requires a willingness to update beliefs as new data emerges.

Is TRT Safe for the Heart? What the FDA Testosterone Panel Said

Heart risk has been another loud warning attached to testosterone for years. For many men, it was the reason they were told TRT simply wasn’t worth the risk. The TRAVERSE trial changed that conversation.

With over 5,000 men followed, including those with existing cardiovascular risk, the study found no increase in major cardiac events with testosterone therapy.

When the FDA removed the cardiovascular black box warning in early 2025, it acknowledged what the data had already shown. The December FDA panel reinforced that point: appropriate screening and monitoring matter far more than fear-based avoidance.

Here are some key points from the TRAVERSE trial:

  • Over 5,200 men aged 45 to 80 were followed.
  • Participants had existing or high cardiovascular risk.
  • Rates of major cardiac events were similar between testosterone and placebo groups.

Why Is Testosterone Still a Controlled Substance?

Testosterone’s classification as a Schedule III controlled substance wasn’t designed with patient care in mind. It was a response to illicit steroid abuse, not evidence-based testosterone therapy.

Decades later, that classification still shapes how testosterone is perceived and accessed. And when legitimate care becomes hard to obtain, men don’t stop looking for answers. They just find them elsewhere, often without proper oversight.

That’s how you end up with fragmented care, poor oversight, and unnecessary TRT risk. According to panel experts, Schedule III status contributes to:

  • Increased stigma around testosterone therapy
  • Limited access through traditional medical channels (and difficulty maintaining a steady supply of medication) 
  • Growth of unregulated alternatives

Who Is TRT Meant For? FDA Labels vs. Medical Guidelines

One of the most frustrating realities for patients is being told two conflicting things at once: your symptoms and labs qualify you for TRT, but the FDA says otherwise. Currently, TRT approval is limited to men whose low testosterone is caused by specific disorders of the testes or brain. 

Right now, testosterone policy doesn’t reflect how low T shows up in real life. Men can feel the symptoms, see it in their labs, and still hit roadblocks because the official labeling hasn’t caught up.

Panelists called on the FDA to update testosterone indications so physicians can focus on treating patients, not navigating outdated rules that no longer match the science.

What the FDA Testosterone Panel Means for Men

The FDA testosterone panel probably won’t bring immediate policy changes, but it marks an important shift in tone and direction. For men already on TRT, this discussion validates what evidence-based clinics like Victory Men’s Health have practiced for years. 

For men considering therapy, it offers reassurance that many of the fears surrounding testosterone are being reevaluated. Here’s what it means in practical terms:

  • Testosterone deficiency is increasingly recognized as a legitimate health issue
  • Fear-based barriers to care are being challenged
  • Individualized, symptom-based treatment remains essential

The message from the panel was one we wholeheartedly agree with: testosterone therapy should be guided by evidence, not stigma.

It’s Time to Abandon Fear-Based TRT Policy

While regulatory change takes time, it’s clear that many of the fears that shaped TRT policy for decades are no longer supported by current evidence. Testosterone deficiency is a real medical condition that affects your health, quality of life, and long-term outcomes. 

At Victory Men’s Health, this science-first approach has always guided our care. We prioritize symptom-based evaluation and personalized treatment plans designed to support long-term health.

TB006 for Alzheimer’s: What We Know So Far About This Galectin-3 Therapy

Posted on by AmyADMIN

Most people searching for new Alzheimer’s disease (AD) treatments are looking for something that could meaningfully change day-to-day function: memory, independence, communication, and quality of life. That’s why TB006, an investigational Alzheimer’s therapy, has become a topic of growing interest based on early signals reported in some patients.

We recently attended a medical conference where TB006 was one of the most discussed therapies in the Alzheimer’s space. It stood out because it challenges the “single-target” approach that has dominated AD for years and instead focuses on a pathway tied to both neuroinflammation and toxic protein aggregation.

TB006 is still in clinical development and is not FDA-approved. Today, access has largely come through clinical trials and an FDA-authorized Expanded Access (compassionate use) pathway for certain patients who meet criteria.

What Is TB006 and How Does It Work?

TB006 is an investigational monoclonal antibody that targets galectin-3 and is being studied as a potential new treatment for Alzheimer’s disease.

Most Alzheimer’s drugs focus on managing symptoms or addressing plaques after damage has already occurred. TB006 takes a different approach by targeting galectin-3, a protein tied to chronic inflammation in the brain and the biological environment that allows plaque formation to continue. That distinction matters because it reflects a broader shift in how Alzheimer’s disease is being understood and studied.

At this stage, it is administered as a monthly IV therapy.

While it’s primarily being researched for Alzheimer’s disease, there’s growing interest in Parkinson’s disease as well. What makes TB006 different isn’t how it’s given. It’s what it targets.

What’s Galectin-3?

Galectin-3 is a protein that shows up in much higher levels in the brains of people with Alzheimer’s disease. Over time, researchers have realized galectin-3 does more than just hang around in damaged brain tissue.

Galectin-3 appears to:

  • Help amyloid proteins clump together
  • Act like scaffolding that supports plaque buildup
  • Fuel ongoing inflammation in the brain
  • Keep the disease process “turned on”

In basic terms, galectin-3 helps create the environment where Alzheimer’s disease can continue to progress.

What Is TB006 Trying to Do?

TB006 is designed to bind to galectin-3 and block its ability to do those things. By targeting galectin-3 directly, the goal is to:

  • Slow down amyloid aggregation
  • Disrupt plaque formation
  • Reduce inflammatory signaling
  • Support healthier communication between brain cells

Most Alzheimer’s disease drugs focus on cleaning up plaques after the damage is done. TB006 is trying to interfere earlier in the process, at the level of inflammation and protein behavior. That shift is why researchers are paying attention.

What the Research Shows So Far

At the conference, the number that kept coming up was this: roughly 47% of patients receiving the IV reported significant improvement. That is not a small claim in Alzheimer’s research, and it is why the chatter around TB006 is so loud right now.

They also showed before-and-after examples that were hard to ignore. One patient went from struggling with basic movement to moving much more freely after treatment. That kind of change gets attention. However, it is also not the same thing as long-term clinical proof.

Two other important takeaways came up in the discussion:

  • Response time varies. Some people appear to notice changes after one infusion. Others may need three to six months before anything shifts.
  • Not everyone responds. There is also a genetic factor being discussed, where one specific SNP may predict non-response.

The signal is exciting. There are limitations though. And the next steps depend on what the trials prove.

What TB006 Treatment Looks Like

At the moment, TB006 is expensive (3K per IV), limited in access, investigation, and not part of standard Alzheimer’s care. 

Right now, TB006 is studied as:

  • An IV infusion
  • About one hour per session
  • Given every 28 days
  • Intended as ongoing treatment, not a one-time fix

Is TB006 Being Studied for Parkinson’s Disease?

Yes, TB006 is also being studied for Parkinson’s disease. Galectin-3 is involved in inflammation and protein aggregation beyond Alzheimer’s disease. In Parkinson’s disease, similar processes occur with different proteins, like alpha-synuclein. 

Because galectin-3 plays a role in how these proteins clump and how inflammation stays active, researchers are exploring whether targeting it could help across multiple neurodegenerative conditions.

Parkinson’s is an area of interest and trials are underway. 

TB006 and the Future of Alzheimer’s Treatment

TB006 reinforces that Alzheimer’s disease is not just about plaques. It’s about inflammation, immune signaling, and the biological environment that allows damage to continue.

By targeting galectin-3, TB006 helps move the conversation forward, highlighting that Alzheimer’s is more complex than amyloid plaque alone. This IV-based treatment supports the idea that effective Alzheimer’s plaque removal therapy may need to address inflammation and aggregation together, not separately.

From our perspective, that’s progress. This is how better treatments are built. Not overnight and not perfectly, but by slowly improving how we understand the disease itself.

Questions Our Patients Are Asking About TB006

What Is TB006 Used For?

TB006 is an investigational therapy being studied primarily as an Alzheimer’s disease medication. It targets galectin-3, a protein involved in inflammation and plaque formation.

Is TB006 FDA Approved?

No. TB006 is still in clinical trials and is not yet FDA approved.

How Is TB006 Different From Other Alzheimer’s Disease Drugs?

Most Alzheimer’s disease drugs focus on symptoms or plaque removal alone. TB006 targets galectin-3, which plays a role in both inflammation and plaque development.

Does TB006 Remove Alzheimer’s Plaques?

TB006 is designed to interfere with plaque formation and may support plaque reduction, but research is ongoing and results are still being evaluated.

When Will TB006 Become Widely Available?

That depends on the outcome of TB006 clinical trials and the FDA approval process. Realistically, this could take several years.